You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunoglobulin Fc Fragments

Showing 1 - 25 of 1,557
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Natural Killer T Cells ExpressingInvariant T Receptor :

Not yet recruiting
  • Systemic Lupus Erythematosus
  • Physiopathology
  • Blood sample
  • Tours, France
    University Hospital
May 12, 2023

COVID-19 Trial in Monterrey (Placebo, Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS))

Recruiting
  • COVID-19
  • Placebo
  • Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)
  • Monterrey, Nuevo Leon, Mexico
    Hospital San José
Oct 20, 2021

Immunoglobulin A Nephropathy Trial (SM101, Placebo)

Withdrawn
  • Immunoglobulin A Nephropathy
  • SM101
  • Placebo
  • (no location specified)
Feb 3, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in Guangzhou (RC18 160mg, RC18 240mg)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • RC18 160mg
  • RC18 240mg
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital,Sun Yat-Sen University
Jan 7, 2022

Primary Sjögren's Syndrome Trial in Yantai (Placebo, RC18 240 mg, RC18 160 mg)

Completed
  • Primary Sjögren's Syndrome
  • Placebo
  • +2 more
  • Yantai, Shandong, China
    Remegen,Ltd.
Jan 7, 2022

Neuromyelitis Optica Spectrum Disorders Trial in Beijing (Placebo, RC18 160 mg)

Recruiting
  • Neuromyelitis Optica Spectrum Disorders
  • Placebo
  • RC18 160 mg
  • Beijing, Beijing, China
    Beijing Hospital
Jan 9, 2022

Metabolic-associated Fatty Liver Disease, Type 2 Diabetes Trial (Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide)

Not yet recruiting
  • Metabolic-associated Fatty Liver Disease
  • Type 2 Diabetes
  • (no location specified)
Oct 1, 2022

Systemic Myasthenia Gravis Trial in Beijing (RC18 160mg, RC18 240 mg)

Active, not recruiting
  • Systemic Myasthenia Gravis
  • RC18 160mg
  • RC18 240 mg
  • Beijing, Beijing, China
    Beijing Tiantan Hospital,Capital Medical University
Jan 9, 2022

Thalassemia Major, Transfusion-dependent Anemia Trial in Guangzhou (Luspatercept Injectable Product)

Recruiting
  • Thalassemia Major
  • Transfusion-dependent Anemia
  • Luspatercept Injectable Product
  • Guangzhou, Guangdong, China
    The second affiliated hospital of Sun Yat-sen University
Jul 15, 2022

Myelodysplastic/Myeloproliferative Tumor With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Tumor,

Recruiting
  • Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 6, 2023

Type 2 Diabetes Trial in Shijia Zhuang (TG103,Q2W, TG103,QW, Placebo,Q2W)

Not yet recruiting
  • Type 2 Diabetes Mellitus
  • Shijia Zhuang, Hebei, China
    Gao Huanhuan
Jun 9, 2022

Hemophilia A Trial in Moscow (Efmoroctocog Alfa Injection [Eloctate])

Recruiting
  • Hemophilia A
  • Efmoroctocog Alfa Injection [Eloctate]
  • Moscow, Russian Federation
    League of Clinical Research (LeagueCRR)
Apr 6, 2022

Neovascular Age-Related Macular Degeneration Trial in Shanghai (HB002.1M)

Completed
  • Neovascular Age-Related Macular Degeneration
  • Shanghai, Shanghai, China
    Shanghai General Hospital
Jul 28, 2020

Hemophilia A Trial in China (Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection)

Active, not recruiting
  • Hemophilia A
  • Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
  • Hefei, Anhui, China
  • +16 more
Apr 13, 2021

Malignant Tumor of Digestive System Trial in Hanzhou (DR30303)

Recruiting
  • Malignant Neoplasm of Digestive System
  • Hanzhou, Zhejiang, China
    Sir Run Run Shaw Hospital，Zhejiang University School of Medicine
Nov 24, 2022

Guillain-Barre Syndrome Trial in Zhengzhou (immunosorbent column, intravenous immunoglobulin)

Not yet recruiting
  • Guillain-Barre Syndrome
  • immunosorbent column
  • intravenous immunoglobulin
  • Zhengzhou, Henan, China
    First Affiliated Hospital of Zhengzhou University
Oct 6, 2022

Kidney Transplantation in Highly Sensitized Patients Trial in United States (drug, procedure, other)

Recruiting
  • Kidney Transplantation in Highly Sensitized Patients
  • Birmingham, Alabama
  • +12 more
Jan 12, 2023

Severe Hemophilia A Trial in China (FRSW117)

Not yet recruiting
  • Severe Hemophilia A
  • Beijing, China
  • +27 more
Nov 16, 2023

Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases Trial in United States (Botensilimab, Balstilimab)

Recruiting
  • Advanced Cancer
  • +7 more
  • Scottsdale, Arizona
  • +14 more
Sep 15, 2022

COPD Exacerbation Acute Trial in Rochester (CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy)

Not yet recruiting
  • COPD Exacerbation Acute
  • CUVITRU - Ig subcutaneous human 20%
  • Standard Medical Therapy
  • Rochester, New York
  • +2 more
Feb 28, 2023

Clostridium Infection Trial in Paris (Collection of peripheral blood mononuclear cells)

Completed
  • Clostridium Infection
  • Collection of peripheral blood mononuclear cells
  • Paris, France
    Maladies infectieuses et tropicales, Hôpital Pitié-Salpêtrière
Oct 3, 2022

Kidney Transplantation in Highly Sensitized Patients Trial in Prague, Barcelona, Madrid (Imlifidase, Normal Transplantation

Recruiting
  • Kidney Transplantation in Highly Sensitized Patients
  • Vienna, Austria
  • +9 more
Jan 24, 2023

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer Trial in Germany, Spain,

Recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • Essen, Germany
  • +5 more
Nov 15, 2022

Kidney Transplantation in Highly Sensitized Patients Trial in New York (Imlifidase)

Not yet recruiting
  • Kidney Transplantation in Highly Sensitized Patients
  • New York, New York
    NYU Langone Health Transplant Institute
Sep 9, 2021

Idiopathic Pulmonary Fibrosis, Acute Fatal Form Trial in United States (Autoantibody Reductive Therapy, Treatment as Usual

Recruiting
  • Idiopathic Pulmonary Fibrosis, Acute Fatal Form
  • Autoantibody Reductive Therapy
  • Treatment as Usual (TAU)
  • Birmingham, Alabama
  • +6 more
Sep 5, 2022